VIP could be used as asthma treatment

GC, MDGC

VIP could be used as asthma treatment

22 Nov, 2011

Published over 14 years ago. See the latest and most current information on GC, MDGC.

The effect of Vasoactive Intestinal Peptide (VIP) on asthma has been studied in order to shed light on any potential treatments.

In a report published by BMC Immunology journal, a team from the SUNY Stony Brook School of Medicine in the US noted that previous investigations had identified a number of unusual features of asthma in Vasoactive Intestinal Peptide knockout mice (VIP KO).

They found that there was peribronchiolar airway inflammation, with accumulation of lymphocytes and eosinophils, some pro-inflammatory cytokine production and airway hyper-responsiveness to inhaled methacholine.

Using mass chromatography processes, the team sought to examine the role of VIP in modulating anti-oxidant genes and their proteins, including lung carbonyl reductase.

Four male VIP KO mice and four wild-type age- and gender-matched mice were examined and it was found that a novel variant of anti-oxidant protein lung carbonyl reductase (car3) was uniquely and markedly elevated in the VIP KO mice.

The findings suggest that VIP influences the endogenous oxidant/antioxidant balance and may mean that it could be used as a treatment for inflammatory diseases.

Posted by Neil Clark

Explore Our Other Sites

Labmate Online
Green analytical chemistry review calls for integrated sustainability metrics and AI to improve pharmaceutical analysis
Explore more Arrow
Envirotech Online
England's rivers and lakes: what the 2025 data really shows about pollution drivers
Explore more Arrow
Pollution Solutions Online
Leading UK biogas operator places first orders for new FlowSep technology
Explore more Arrow
Petro Online
EU E20 plans could create a new testing workload for fuel laboratories
Explore more Arrow